FGF21 and metabolic dysfunction-associated steatotic liver disease: Considering its multiple metabolic benefits, several clinical trials have been registered to evaluate the therapeutic efficacy of human FGF21 analogues (LY2405319, PF‐05231023, PF‐05231023, BMS‐986036) for the treatment of T2DM, dyslipidaemia and NAFLD, and positive results have been achieved.11